Impax Labs sued by Johnson & Johnson unit over Concerta patent
In a second law suit filed against it in a matter of days, US generic drugmaker Impax Laboratories (Nasdaq: IPXL) says that Alza Corp, a subsidiary of drug major Johnson & Johnson (NYSE: JNJ), has filed suit for patent infringement against Impax in the US District Court for the District of Delaware in connection with Concerta (methylphenidate hydrochloride) extended-release 54mg tablets, a treatment for attention-deficit hyperactivity disorder (ADHD).
Earlier this week, Impax was also sued by Abbott Laboratories for patent infringement of the latter’s cholesterol lowering drug Simcor (niacin/simvastatin; The Pharma Letter November 29). Impax shares fell 2% to $18.77 on the latest news.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze